VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: PR Newswire
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer DetectionHENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. Frédéric Wuilque, VP-Global Products, Volition commented :"Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years."Our mission is
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- Volition Sponsors Symposium at Veterinary Meeting and ExpoPR Newswire
- VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.MarketBeat
- VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]Yahoo! Finance
- VolitionRx Secures $2.0 Million in FundingPR Newswire
- VolitionRx (NYSE:VNRX) had its price target lowered by analysts at D. Boral Capital from $5.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
VNRX
Earnings
- 11/13/25 - Miss
VNRX
Sec Filings
- 1/8/26 - Form 8-K
- 12/11/25 - Form 8-K
- 11/17/25 - Form 4
- VNRX's page on the SEC website